A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
NCT04626921 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2023-12-08
Summary
Open-label, long-term extension study available to participants who have completed CNMAu8.201.
Conditions
Interventions
- DRUG
-
CNM-Au8
30 mg of CNM-Au8
Sponsors & Collaborators
-
George Clinical
collaborator UNKNOWN -
Clene Nanomedicine
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-22
- Primary Completion
- 2023-05-29
- Completion
- 2023-09-06
- FDA Drug
- Yes
Countries
- Australia
Study Locations
More Related Trials
-
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
NCT03996291 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
NCT02861014 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
NCT02792231 ·Status: COMPLETED ·Phase: PHASE3
-
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years
NCT01084798 ·Status: COMPLETED
-
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
NCT05906992 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
NCT00340834 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
NCT01201356 ·Status: COMPLETED ·Phase: PHASE3
-
Home Based Infusions for Ocrelizumab
NCT04650321 ·Status: RECRUITING ·Phase: PHASE4
-
Mechanistic Studies of Teriflunomide in RRMS
NCT03464448 ·Status: COMPLETED
-
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
NCT03085810 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
NCT01081782 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT00662649 ·Status: COMPLETED ·Phase: PHASE3
-
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response
NCT03316404 ·Status: COMPLETED
-
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
NCT07085507 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Home-based Action Observation Treatment With Virtual-reality for Arm Rehabilitation in People With Multiple Sclerosis
NCT05713890 ·Status: RECRUITING ·Phase: NA
-
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853 ·Status: COMPLETED
-
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
NCT02792218 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292 ·Status: RECRUITING ·Phase: PHASE3
-
Cellular microRNA Signatures in Multiple Sclerosis
NCT05290688 ·Status: UNKNOWN ·Phase: NA
-
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance
NCT01156298 ·Status: TERMINATED
-
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
NCT03689972 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
NCT05232825 ·Status: COMPLETED ·Phase: PHASE3